Insider Trading Alert - METR, MNTA And PRI Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, May 20, 2015, 100 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $186.58 to $190,703,600.00.

Highlighted Stocks Traded by Insiders:

Metro Bancorp (METR) - FREE Research Report

Smida Thomas F, who is Director at Metro Bancorp, bought 380 shares at $26.52 on May 20, 2015. Following this transaction, the Director owned 780 shares meaning that the stake was boosted by 95% with the 380-share transaction.

The shares most recently traded at $26.17, down $0.35, or 1.35% since the insider transaction. Historical insider transactions for Metro Bancorp go as follows:

  • 4-Week # shares bought: 100
  • 4-Week # shares sold: 2,826
  • 12-Week # shares bought: 100
  • 12-Week # shares sold: 2,826
  • 24-Week # shares bought: 100
  • 24-Week # shares sold: 9,232

The average volume for Metro Bancorp has been 19,400 shares per day over the past 30 days. Metro Bancorp has a market cap of $376.8 million and is part of the financial sector and banking industry. Shares are up 2.62% year-to-date as of the close of trading on Wednesday.

Metro Bancorp, Inc. operates as the bank holding company for Metro Bank that offers retail and commercial banking services for consumers, and small and mid-sized companies in Pennsylvania. The stock currently has a dividend yield of 0.53%. The company has a P/E ratio of 17.6. Currently, there are no analysts who rate Metro Bancorp a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on METR - FREE

TheStreet Quant Ratings rates Metro Bancorp as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, compelling growth in net income, solid stock price performance and reasonable valuation levels. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Metro Bancorp Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Momenta Pharmaceuticals (MNTA) - FREE Research Report

Kaundinya Ganesh Venkataraman, who is Senior V.P., Research at Momenta Pharmaceuticals, sold 406 shares at $19.63 on May 20, 2015. Following this transaction, the Senior V.P., Research owned 389,012 shares meaning that the stake was reduced by 0.1% with the 406-share transaction.

Shea Richard P, who is Svp, Cfo at Momenta Pharmaceuticals, sold 406 shares at $19.63 on May 20, 2015. Following this transaction, the Svp, Cfo owned 144,275 shares meaning that the stake was reduced by 0.28% with the 406-share transaction.

Bishop John E, who is Senior VP, Pharmaceutical Scie at Momenta Pharmaceuticals, sold 624 shares at $19.63 on May 20, 2015. Following this transaction, the Senior VP, Pharmaceutical Scie owned 110,861 shares meaning that the stake was reduced by 0.56% with the 624-share transaction.

Leicher Bruce, who is SVP & General Counsel at Momenta Pharmaceuticals, sold 426 shares at $19.63 on May 20, 2015. Following this transaction, the SVP & General Counsel owned 118,044 shares meaning that the stake was reduced by 0.36% with the 426-share transaction.

Roach James M., who is Senior VP, Development and Chi at Momenta Pharmaceuticals, sold 617 shares at $19.63 on May 20, 2015. Following this transaction, the Senior VP, Development and Chi owned 106,262 shares meaning that the stake was reduced by 0.58% with the 617-share transaction.

The shares most recently traded at $19.16, down $0.47, or 2.45% since the insider transaction. Historical insider transactions for Momenta Pharmaceuticals go as follows:

  • 4-Week # shares sold: 37,197
  • 12-Week # shares sold: 129,275
  • 24-Week # shares sold: 159,381

The average volume for Momenta Pharmaceuticals has been 952,000 shares per day over the past 30 days. Momenta Pharmaceuticals has a market cap of $1.1 billion and is part of the health care sector and drugs industry. Shares are up 60.22% year-to-date as of the close of trading on Wednesday.

Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for oncology and autoimmune diseases. Currently, there are 4 analysts who rate Momenta Pharmaceuticals a buy, 1 analyst rates it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on MNTA - FREE

TheStreet Quant Ratings rates Momenta Pharmaceuticals as a sell. The area that we feel has been the company's primary weakness has been its unimpressive growth in net income. Get the full Momenta Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Primerica (PRI) - FREE Research Report

Williams Glenn J., who is President at Primerica, sold 3,000 shares at $45.50 on May 20, 2015. Following this transaction, the President owned 64,732 shares meaning that the stake was reduced by 4.43% with the 3,000-share transaction.

The shares most recently traded at $45.86, up $0.36, or 0.77% since the insider transaction. Historical insider transactions for Primerica go as follows:

  • 4-Week # shares sold: 30,000
  • 12-Week # shares sold: 123,669
  • 24-Week # shares sold: 150,046

The average volume for Primerica has been 406,400 shares per day over the past 30 days. Primerica has a market cap of $2.3 billion and is part of the financial sector and insurance industry. Shares are down 15.41% year-to-date as of the close of trading on Wednesday.

Primerica, Inc., together with its subsidiaries, distributes financial products to middle income households in the United States and Canada. The company operates in three segments: Term Life Insurance; Investment and Savings Products; and Corporate and Other Distributed Products. The stock currently has a dividend yield of 1.4%. The company has a P/E ratio of 13.9. Currently, there is 1 analyst who rates Primerica a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PRI - FREE

TheStreet Quant Ratings rates Primerica as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, notable return on equity, largely solid financial position with reasonable debt levels by most measures and increase in stock price during the past year. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full Primerica Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Global Markets Hit Hard; AMC Entertainment Sells Stake in Ad Unit -- ICYMI

Global Markets Hit Hard; AMC Entertainment Sells Stake in Ad Unit -- ICYMI

CVS, Walgreens and Citigroup: Cramer's 'Off the Charts'

CVS, Walgreens and Citigroup: Cramer's 'Off the Charts'

Jim Cramer: 4 Stocks Could Get Throttled By a 'Knock Down Drag Out' With China

Jim Cramer: 4 Stocks Could Get Throttled By a 'Knock Down Drag Out' With China

General Electric Booted From Dow, Replaced by Walgreens

General Electric Booted From Dow, Replaced by Walgreens

Dow Plunges on Trade War Worries but Walmart and Verizon Finish Positively

Dow Plunges on Trade War Worries but Walmart and Verizon Finish Positively